雾化吸入用药在新冠肺炎疫情中的研究现状
Research Status of Aerosol Inhalation Drugs in COVID-19 Outbreak
DOI: 10.12677/ACM.2021.118508, PDF,   
作者: 秦浩然：青海大学，青海 西宁；李忠诚#：青海大学附属医院胸外科，青海 西宁
关键词: 新型冠状病毒肺炎；2019新型冠状病毒；雾化吸入；给药途径；Corona Virus Disease 2019； SARS-CoV-2； Aerosol Inhalation； Administration Route
摘要: 新型冠状病毒肺炎(Corona Virus Disease 2019, COVID-19) (以下简称“新冠肺炎”)已经造成了全球大爆发、大流行，新冠肺炎患者的研究和临床观察表明，2019新型冠状病毒(SARS-CoV-2)的主要靶点是肺。雾化吸入作为一种以肺为主要靶器官的直接给药方法，在治疗呼吸系统相关疾病中发挥着重要作用。但是目前，针对于COVID-19的全球大流行态势，雾化吸入用药的优势尚未被有效利用，本文旨在对新冠肺炎疫情中对雾化吸入用药的研究现状进行综述，为新冠肺炎患者治疗期间雾化吸入用药提供参考。
Abstract: COVID-19 (Corona Virus Disease 2019) (hereinafter referred to as “COVID-19”) has produced a global outbreak, pandemic, COVID-19 patient studies and clinical observations have shown that the main target of the Novel Corona virus 2019 (SARS-COV-2) is the lung. Aerosol inhalation, as a direct drug delivery method with the lung as the main target organ, plays an important role in the treatment of respiratory diseases. However, in view of the global pandemic situation of COVID-19, the advantages of aerosol inhalation medication have not been effectively utilized. This paper aims to review the research status of aerosol inhalation medication in COVID-19 epidemic, and provide reference for aerosol inhalation medication during the treatment of COVID-19 patients.
文章引用：秦浩然, 李忠诚. 雾化吸入用药在新冠肺炎疫情中的研究现状[J]. 临床医学进展, 2021, 11(8): 3487-3492. https://doi.org/10.12677/ACM.2021.118508

参考文献

[1] Domenico, C. and Maurizio, V. (2020) WHO Declares COVID-19 a Pandemic. Acta Biomedica Atenei Parmensis, 91, 157-160.
[2] Zhe, X., et al. (2020) Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome. The Lancet Respiratory Medicine, 8, 420-422. [Google Scholar] [CrossRef] 
[3] Wichmann, D., et al. (2020) Autopsy Findings and Venous Thromboembolism in Patients with COVID-19. Annals of Internal Medicine, 173, 1030. [Google Scholar] [CrossRef] 
[4] Wu, Z.Y. and McGoogan, J.M. (2020) Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA, 323, 1239-1242. [Google Scholar] [CrossRef] [PubMed]
[5] Huang, C.L., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506. [Google Scholar] [CrossRef] 
[6] Zhou, P., et al. (2020) A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature, 579, 270-273. [Google Scholar] [CrossRef] [PubMed]
[7] 杜光, 赵杰, 卜书红, 陈娜, 陈瑞玲, 陈万生, 陈孝, 陈泳伍, 戴智勇, 杜光, 冯瑾, 高杰, 高申, 葛卫红, 郭瑞臣, 菅凌燕, 姜玲, 李峰, 李佳, 李玉萍, 刘皋林, 卢晓阳, 吕迁州, 闵光宁, 缪丽燕, 沈承武, 隋忠国, 童荣生, 王春革, 王卓, 武新安, 徐珽, 叶晓芬, 尹桃, 游一中, 张健, 张玮, 张文婷, 张晓坚, 赵杰, 赵志刚, 朱立勤, 邹东娜. 雾化吸入疗法合理用药专家共识(2019年版) [J]. 医药导报, 2019, 38(2): 135-146.
[8] Meyerowitz, E.A., Richterman, A., Gandhi, R.T. and Sax, P.E. (2020) Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Annals of Internal Medicine, 174, 69-79. [Google Scholar] [CrossRef] 
[9] Ari, A. (2020) Practical Strategies for a Safe and Effective Delivery of Aerosolized Medications to Patients with COVID-19. Respiratory Medicine, 167, Article ID: 105987. [Google Scholar] [CrossRef] [PubMed]
[10] Ignarro, L.J. (2000) Nitric Oxide: Biology and Pathobiology. Academic Press, Cambridge.
[11] Lu, R.J., et al. (2020) Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding. The Lancet, 395, 565-574. [Google Scholar] [CrossRef] 
[12] Daniel, W., et al. (2020) Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. Science (New York, N.Y.), 367, 1260-1263. [Google Scholar] [CrossRef] [PubMed]
[13] Schmidt, E.P., et al. (2012) The Pulmonary Endothelial Glycocalyx Regulates Neutrophil Adhesion and Lung Injury during Experimental Sepsis. Nature Medicine, 18, 1217-1223. [Google Scholar] [CrossRef] [PubMed]
[14] Uchimido, R., Schmidt, E.P. and Shapiro, N.I. (2019) The Glycocalyx: A Novel Diagnostic and Therapeutic Target in Sepsis. Critical Care (London, England), 23, 16. [Google Scholar] [CrossRef] [PubMed]
[15] Cabrales, P., Tsai, A.G., Frangos, J.A. and Intaglietta, M. (2005) Role of Endothelial Nitric Oxide in Microvascular Oxygen Delivery and Consumption. Free Radical Biology and Medicine, 39, 1229-1237. [Google Scholar] [CrossRef] [PubMed]
[16] Sara, A., et al. (2005) Nitric Oxide Inhibits the Replication Cycle of Severe Acute Respiratory Syndrome Coronavirus. Journal of Virology, 79, 1966-1969. [Google Scholar] [CrossRef] 
[17] Zhang, R.L., et al. (2015) Hemoglobin βCys93 Is Essential for Cardiovascular Function and Integrated Response to Hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 112, 6425-6430. [Google Scholar] [CrossRef] [PubMed]
[18] Cabrales, P. (2013) Examining and Mitigating Acellular Hemoglobin Vasoactivity. Antioxidants & Redox Signaling, 18, 2329-2341. [Google Scholar] [CrossRef] [PubMed]
[19] Moncada, S. and Higgs, A. (1993) The L-Arginine-Nitric Oxide Pathway. The New England Journal of Medicine, 329, 2002-2012. [Google Scholar] [CrossRef] 
[20] Lee, H.-Y., Zeeshan, H.M.A., Kim, H.-R. and Chae, H.-J. (2017) Nox4 Regulates the eNOS Uncoupling Process in Aging Endothelial Cells. Free Radical Biology and Medicine, 113, 26-35. [Google Scholar] [CrossRef] [PubMed]
[21] Csoma, B., et al. (2019) Dysregulation of the Endothelial Nitric Oxide Pathway Is Associated with Airway Inflammation in COPD. Respiratory Research, 20, Article No. 156. [Google Scholar] [CrossRef] [PubMed]
[22] Lopez-Sublet, M., et al. (2018) Focus on Increased Serum Angiotensin-Converting Enzyme Level: From Granulomatous Diseases to Genetic Mutations. Clinical Biochemistry, 59, 1-8. [Google Scholar] [CrossRef] [PubMed]
[23] Wang, J., et al. (2015) Balance between Angiotensin Converting Enzyme and Angiotensin Converting Enzyme 2 in Patients with Chronic Heart Failure. Journal of the Renin-Angiotensin-Aldosterone System, 16, 553-558. [Google Scholar] [CrossRef] [PubMed]
[24] Bateman, E.D., et al. (2018) Global Strategy for Asthma Management and Prevention: GINA Executive Summary. E.D. Bateman, S.S. Hurd, P.J. Barnes, J. Bousquet, J.M. Drazen, J.M. FitzGerald, P. Gibson, K. Ohta, P. O’Byrne, S.E. Pedersen, E. Pizzichini, S.D. Sullivan, S.E. Wenzel and H.J. Zar. Eur Respir J 2008; 31: 143-178. The European Respiratory Journal, 51, Article ID: 0751387. [Google Scholar] [CrossRef] [PubMed]
[25] Rahman, M.M. and Siddiqui, M.M.R. (2016) Global Initiative for Chronic Obstructive Lung Disease (GOLD). Anwer Khan Modern Medical College Journal, 7, 4. [Google Scholar] [CrossRef] 
[26] Yang, M.J., et al. (2019) Inhaled Corticosteroids and Risk of Upper Respiratory Tract Infection in Patients with Asthma: A Meta-Analysis. Infection, 47, 377-385. [Google Scholar] [CrossRef] [PubMed]
[27] Yang, M.J., et al. (2017) Long-Term Use of Inhaled Corticosteroids and Risk of Upper Respiratory Tract Infection in Chronic Obstructive Pulmonary Disease: A Meta-Analysis. Inhalation Toxicology, 29, 219-226. [Google Scholar] [CrossRef] [PubMed]
[28] Yang, I.A., et al. (2012) Inhaled Corticosteroids for Stable Chronic Obstructive Pulmonary Disease. The Cochrane Database of Systematic Reviews, No. 7, CD002991. [Google Scholar] [CrossRef] 
[29] Marco, C., et al. (2017) Long-Term Effects of Inhaled Corticosteroids on Sputum Bacterial and Viral Loads in COPD. The European Respiratory Journal, 50, Article ID: 1700451. [Google Scholar] [CrossRef] [PubMed]
[30] Antonio, A., et al. (2017) Inhalation Therapies in Acute Respiratory Distress Syndrome. Annals of Translational Medicine, 5, 293. [Google Scholar] [CrossRef] [PubMed]
[31] Ortiz-Diaz, E., et al. (2011) Preadmission Use of Inhaled Corticosteroids Is Associated with a Reduced Risk of Direct Acute Lung Injury/Acute Respiratory Distress Syndrome. Chest, 140, 912A, 912B. [Google Scholar] [CrossRef] 
[32] Emir, F., et al. (2017) Randomized Clinical Trial of a Combination of an Inhaled Corticosteroid and Beta Agonist in Patients at Risk of Developing the Acute Respiratory Distress Syndrome. Critical Care Medicine, 45, 798-805. [Google Scholar] [CrossRef] 
[33] Yamaya, M., et al. (2020) Inhibitory Effects of Glycopyrronium, Formoterol, and Budesonide on Coronavirus HCoV-229E Replication and Cytokine Production by Primary Cultures of Human Nasal and Tracheal Epithelial Cells. Respiratory Investigation, 58, 155-168. [Google Scholar] [CrossRef] [PubMed]
[34] Oliver, B.G.G., Robinson, P., Peters, M. and Black, J. (2014) Viral Infections and Asthma: An Inflammatory Interface? The European Respiratory Journal, 44, 1666-1681. [Google Scholar] [CrossRef] [PubMed]
[35] Singanayagam, R., et al. (2018) Corticosteroid Suppression of Antiviral Immunity Increases Bacterial Loads and Mucus Production in COPD Exacerbations. Nature Communications, 9, Article No. 2229. [Google Scholar] [CrossRef] [PubMed]
[36] Halpin, D.M.G., Singh, D. and Hadfield, R.M. (2020) Inhaled Corticosteroids and COVID-19: A Systematic Review and Clinical Perspective. The European Respiratory Journal, 55, Article ID: 2001009. [Google Scholar] [CrossRef] [PubMed]
[37] Horby, P., et al. (2020) Dexamethasone in Hospitalized Patients with Covid-19—Preliminary Report. The New England Journal of Medicine, 384, 693-704. [Google Scholar] [CrossRef] 
[38] Marmor, M.F., et al. (2016) Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology, 123, 1386-1394. [Google Scholar] [CrossRef] [PubMed]
[39] Gautret, P., et al. (2020) Hydroxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. International Journal of Antimicrobial Agents, 56, Article ID: 105949. [Google Scholar] [CrossRef] [PubMed]
[40] Biot, C., et al. (2006) Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities. Journal of Medicinal Chemistry, 49, 2845-2849. [Google Scholar] [CrossRef] [PubMed]
[41] Colson, P., et al. (2020) Chloroquine and Hydroxychloroquine as Available Weapons to Fight COVID-19. International Journal of Antimicrobial Agents, 55, Article ID: 105932. [Google Scholar] [CrossRef] [PubMed]
[42] Yao, X.T., et al. (2020) In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 71, 732-739. [Google Scholar] [CrossRef] [PubMed]
[43] Albariqi, A.H., et al. (2020) Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 34, 20-31. [Google Scholar] [CrossRef] [PubMed]
[44] Chu, D.K., et al. (2020) Physical Distancing, Face Masks, and Eye Protection to Prevent Person-to-Person Transmission of SARS-CoV-2 and COVID-19: A Systematic Review and Meta-Analysis. The Lancet, 395, 1973-1987. [Google Scholar] [CrossRef] 
[45] Dhand, R. and Li, J. (2020) Coughs and Sneezes: Their Role in Transmission of Respiratory Viral Infections, Including SARS-CoV-2. American Journal of Respiratory and Critical Care Medicine, 202, 651-659. [Google Scholar] [CrossRef] 
[46] Fink, J.B., et al. (2020) Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 33, 300-304. [Google Scholar] [CrossRef] [PubMed]
[47] Ari, A. (2020) Use of Aerosolised Medications at Home for COVID-19. The Lancet Respiratory Medicine, 8, 754-756. [Google Scholar] [CrossRef] 
[48] Louis-Philippe, B., et al. (2019) The Global Initiative for Asthma (GINA): 25 Years Later. The European Respiratory Journal, 54, Article ID: 1900598. [Google Scholar] [CrossRef] [PubMed]
[49] Halpin, D.M.G., Faner, R., Sibila, O., Badia, J.R. and Agusti, A. (2020) Do Chronic Respiratory Diseases or Their Treatment Affect the Risk of SARS-CoV-2 Infection? The Lancet Respiratory Medicine, 8, 436-438. [Google Scholar] [CrossRef] 
[50] Tran, K., et al. (2013) Aerosol-Generating Procedures and Risk of Transmission of Acute Respiratory Infections: A Systematic Review. CADTH Technology Overviews, 3, e3201.
[51] Adusumilli, N.C., et al. (2020) Harnessing Nitric Oxide for Preventing, Limiting and Treating the Severe Pulmonary Consequences of COVID-19. Nitric Oxide, 103, 4-8. [Google Scholar] [CrossRef] [PubMed]

为你推荐